Akero Therapeutics (AKRO) Gets a Buy Rating from Jefferies


In a report released today, Michael Yee from Jefferies maintained a Buy rating on Akero Therapeutics (AKRO), with a price target of $48.00. The company’s shares closed last Wednesday at $26.83.

According to TipRanks.com, Yee is a 3-star analyst with an average return of 4.9% and a 47.5% success rate. Yee covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Vertex Pharmaceuticals, and Olema Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akero Therapeutics with a $60.17 average price target, which is a 124.1% upside from current levels. In a report issued on May 14, H.C. Wainwright also maintained a Buy rating on the stock with a $68.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $41.16 and a one-year low of $22.10. Currently, Akero Therapeutics has an average volume of 250K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts